1-6 of 6
Nurit Horesh
Close
Sort by
Journal Articles

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Tamar Berger, Tzippy Shochat, Shlomzion Aumann, Boaz Nachmias, Neta Goldschmidt, Nurit Horesh, Reut Harel, Ariel Aviv, Ella Shmerts, Uri Abadi, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion
Journal: Blood
Blood (2022) 140 (Supplement 1): 11947–11948.
https://doi.org/10.1182/blood-2022-159881
Published: 2022
Journal Articles

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Shimrit Harlev, Nashwa Fadaos, Tehila Azoulay, Ronit Leiba, Nurit Horesh, Tsofia Inbar, Netanel A. Horowitz, Inna Tsoran-Rosenthal, Noa Lavi, Eldad J. Dann, Tsila Zuckerman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6534–6535.
https://doi.org/10.1182/blood-2022-166233
Published: 2022
Journal Articles

In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated

Baher Krayem, Avraham Frisch, Nurit Horesh, Ronit Leiba, Tsila Zuckerman, Yishai Ofran
Journal: Blood
Blood (2021) 138 (Supplement 1): 3378.
https://doi.org/10.1182/blood-2021-152532
Published: 2021
Journal Articles

RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

Ali Khateb, PhD, Anagha Deshpande, PhD, Yongmei Feng, PhD, Ikrame Lazar, PhD, Joo Sang Lee, PhD, Bertrand Fabre, PhD, Yan Li, PhD, Darren Finlay, PhD, Yu Fujita, PhD, Tongwu Zhang, PhD, Ian Pass, PhD, Ido Livneh, PhD, Carol Burian, James R. Mason, MD, Ronit Almog, MD, Nurit Horesh, MD, Yishai Ofran, MD, Kevin Brown, Kristiina Vuori, PhD, Michael Jackson, PhD, Eytan Ruppin, PhD, Aniruddha J. Deshpande, PhD, Ze'ev A. Ronai, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-143352
Published: 2020
Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2603.
https://doi.org/10.1182/blood-2019-126553
Published: 2019
Journal Articles

Treating Indolent Lymphoma in Older Adults: What Is the Right Way?

Nurit Horesh, MD, Noa Lavi, MD, Eldad Dann, MD, Netanel A. Horowitz, MD
Journal: Blood
Blood (2015) 126 (23): 5097.
https://doi.org/10.1182/blood.V126.23.5097.5097
Published: 2015